article thumbnail

The Competitive Edge of Biosimilars

DrugBank

Biosimilars  Biosimilars, while highly similar to their reference biopharmaceuticals, offer distinct advantages that position them as preferred therapeutic options in many cases. This is because biosimilars are not new drugs but highly similar versions of already approved therapies with established safety and efficacy profiles.

article thumbnail

Exclusive event: Accelerate the development of advanced biotherapeutics

Drug Discovery World

Join DDW for this free event, ‘ Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics ’, which is supported by Revvity. The post Exclusive event: Accelerate the development of advanced biotherapeutics appeared first on Drug Discovery World (DDW).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How can automation help with the discovery of biologics and biosimilars?

Drug Discovery World

Zoe Hughes-Thomas, GSK, will be discussing the ways in which Automation Can Help With The Discovery of Biologics and Biosimilars at the new Tech Theatre at this year’s ELRIG Drug Discovery, supported by DDW. The post How can automation help with the discovery of biologics and biosimilars? Click here? now to register. .

article thumbnail

The Biosimilar Boom and the Coming Humira Price War (Video)

Drug Channels

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilars’ market share is approaching 80%. will face multiple biosimilar competitors. If you missed the live event, you can register to watch a replay and download the full slide deck.

article thumbnail

Decades Later, Congress Continues Debating the Preserve Access to Affordable Generics (and Biosimilars) Act; But will the Recent Jarkesy SCOTUS Decision Finally Put an End to the Insanity?

FDA Law Blog: Biosimilars

Shumsky — As readers of this blog know ( see, e.g. , here ), the Affordable Generics (and Biosimilars) Act has been floating around in Congress for the better part of two decades. The latest iteration of the Preserve Access to Affordable Generics and Biosimilars Act making its way through Congress is Senator Amy Klobuchar’s (D-MN) S.

article thumbnail

Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars

The Pharma Data

Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced a multi-year partnership with Just – Evotec Biologics, the Seattle-based subsidiary of Evotec SE.

article thumbnail

Benefits of higher throughput bioanalytical methods in advanced therapeutics

Drug Discovery World

Join DDW for this free event, ‘ Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics ’, which is supported by Revvity.